newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

  • Chemomab Therapeutics and Scipher Medicine are advancing a proposed all-stock merger expected to close by the end of 2026.
  • The combined company will be valued at $150 million prior to a concurrent $30 million private placement financing.
  • Nebokitug, a first-in-class anti-CCL24 antibody, will advance to a Phase 2 precision medicine trial in rheumatoid arthritis in the first half of 2027 with top-line results expected in the first half of 2028.
  • Scipher's AI SPECTRA platform identified nebokitug as the highest-ranked candidate for rheumatoid arthritis, potentially addressing unmet needs in patients who do not respond to current therapies.
  • Post-merger, the combined entity will operate as Scipher Medicine Corporation trading under the ticker "SCIP" on Nasdaq, with Reg Seeto serving as CEO.
  • Chemomab shareholders will receive approximately 32% of the combined company, while Scipher shareholders will receive approximately 68%.
  • Chemomab shareholders will receive contingent value rights (CVRs) offering $10 million upon FDA approval of nebokitug and $40 million if the PSC program advances to Phase 3 or is partnered.
  • The private placement is led by a syndicate including Northpond Ventures, with 100% warrant coverage based on a $75 million valuation.
  • Nebokitug's cash runway is expected to extend through the Phase 2 rheumatoid arthritis trial readout following the merger closing.
  • Chemomab reported cash and equivalents of $6.7 million as of June 30, 2026, with a net loss of $2.2 million for the second quarter of 2026.
  • Recent data presented at EASL 2026 and DDW 2026 showed nebokitug reduced inflammatory signatures in patients with primary sclerosing cholangitis (PSC) and coexisting inflammatory bowel disease (IBD).
  • Chemomab has confidentially submitted a Form S-4 draft registration statement to the SEC to facilitate the merger review process.